Recent Posts
- StromaCare has raised €1,500,000 for the development of a new oncology therapy based on the immuno-modulation of the tumor stroma using a monoclonal antibody.
- Amoéba: Austria recommends the approval of the biocontrol active substance for the European territory
- Amolyt Pharma announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 in Patients with Hypoparathyroidism
- Amolyt Pharma announces European Commission has granted Orphan drug designation to AZP-3601 for the treatment of Hypoparathyroidism
- Amolyt Pharma selected for the French Tech 120 Program
Archives
- May 2022
- April 2022
- March 2022
- February 2022
- October 2021
- September 2021
- August 2021
- July 2021
- May 2021
- April 2021
- March 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- April 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- March 2019
- February 2019
- December 2018
- November 2018
- December 2017
- September 2017
- April 2017